CLINICAL TRIALS PROFILE FOR SYNTOCINON

All Clinical Trials for SYNTOCINON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00116480 ↗	Misoprostol in the Treatment of Postpartum Hemorrhage	Completed	Aga Khan Health Services	N/A	2005-12-01	Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality, despite treatment with conventional methods. Uncontrolled reports and three small randomised controlled trials have suggested that misoprostol may have an additive effect to routine treatment, and there is a serious danger that this method will be used widely without research to document the effectiveness or risks of this method. In this randomised controlled trial (RCT), we propose to test whether 600 μg of sublingually administered misoprostol in women requiring additional uterotonics after delivery, and after routine syntocinon to all women during or after delivery, has additional effects above the additional conventional uterotonics in reducing PPH. Women with measured blood loss greater than or equal to 500 mls in 4 Karachi hospitals who give consent will be given locally routine treatment for PPH. In addition, they will be enrolled by drawing the next of a series of randomised treatment packs containing misoprostol or placebo. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment.
NCT00116480 ↗	Misoprostol in the Treatment of Postpartum Hemorrhage	Completed	Aga Khan University	N/A	2005-12-01	Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality, despite treatment with conventional methods. Uncontrolled reports and three small randomised controlled trials have suggested that misoprostol may have an additive effect to routine treatment, and there is a serious danger that this method will be used widely without research to document the effectiveness or risks of this method. In this randomised controlled trial (RCT), we propose to test whether 600 μg of sublingually administered misoprostol in women requiring additional uterotonics after delivery, and after routine syntocinon to all women during or after delivery, has additional effects above the additional conventional uterotonics in reducing PPH. Women with measured blood loss greater than or equal to 500 mls in 4 Karachi hospitals who give consent will be given locally routine treatment for PPH. In addition, they will be enrolled by drawing the next of a series of randomised treatment packs containing misoprostol or placebo. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment.
NCT00116480 ↗	Misoprostol in the Treatment of Postpartum Hemorrhage	Completed	Family Care International	N/A	2005-12-01	Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality, despite treatment with conventional methods. Uncontrolled reports and three small randomised controlled trials have suggested that misoprostol may have an additive effect to routine treatment, and there is a serious danger that this method will be used widely without research to document the effectiveness or risks of this method. In this randomised controlled trial (RCT), we propose to test whether 600 μg of sublingually administered misoprostol in women requiring additional uterotonics after delivery, and after routine syntocinon to all women during or after delivery, has additional effects above the additional conventional uterotonics in reducing PPH. Women with measured blood loss greater than or equal to 500 mls in 4 Karachi hospitals who give consent will be given locally routine treatment for PPH. In addition, they will be enrolled by drawing the next of a series of randomised treatment packs containing misoprostol or placebo. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment.
NCT00116480 ↗	Misoprostol in the Treatment of Postpartum Hemorrhage	Completed	The Aga Khan Foundation	N/A	2005-12-01	Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality, despite treatment with conventional methods. Uncontrolled reports and three small randomised controlled trials have suggested that misoprostol may have an additive effect to routine treatment, and there is a serious danger that this method will be used widely without research to document the effectiveness or risks of this method. In this randomised controlled trial (RCT), we propose to test whether 600 μg of sublingually administered misoprostol in women requiring additional uterotonics after delivery, and after routine syntocinon to all women during or after delivery, has additional effects above the additional conventional uterotonics in reducing PPH. Women with measured blood loss greater than or equal to 500 mls in 4 Karachi hospitals who give consent will be given locally routine treatment for PPH. In addition, they will be enrolled by drawing the next of a series of randomised treatment packs containing misoprostol or placebo. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment.
NCT00116480 ↗	Misoprostol in the Treatment of Postpartum Hemorrhage	Completed	Gynuity Health Projects	N/A	2005-12-01	Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality, despite treatment with conventional methods. Uncontrolled reports and three small randomised controlled trials have suggested that misoprostol may have an additive effect to routine treatment, and there is a serious danger that this method will be used widely without research to document the effectiveness or risks of this method. In this randomised controlled trial (RCT), we propose to test whether 600 μg of sublingually administered misoprostol in women requiring additional uterotonics after delivery, and after routine syntocinon to all women during or after delivery, has additional effects above the additional conventional uterotonics in reducing PPH. Women with measured blood loss greater than or equal to 500 mls in 4 Karachi hospitals who give consent will be given locally routine treatment for PPH. In addition, they will be enrolled by drawing the next of a series of randomised treatment packs containing misoprostol or placebo. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment.

Clinical Trial Conditions for SYNTOCINON

Condition Name

Condition Name for SYNTOCINON
Intervention	Trials
Schizophrenia	11
Healthy	8
Postpartum Hemorrhage	8
Oxytocin	7

Condition MeSH

Condition MeSH for SYNTOCINON
Intervention	Trials
Hemorrhage	25
Postpartum Hemorrhage	22
Autistic Disorder	12
Schizophrenia	11

Clinical Trial Locations for SYNTOCINON

Trials by Country

Trials by Country for SYNTOCINON
Location	Trials
United States	70
Egypt	21
Canada	12
United Kingdom	4
Israel	4

Trials by US State

Trials by US State for SYNTOCINON
Location	Trials
California	17
Massachusetts	11
North Carolina	8
New York	8
Maryland	4

Clinical Trial Progress for SYNTOCINON

Clinical Trial Phase

Clinical Trial Phase for SYNTOCINON
Clinical Trial Phase	Trials
Phase 4	16
Phase 3	13
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for SYNTOCINON
Clinical Trial Phase	Trials
Completed	84
Recruiting	14
Unknown status	14

Clinical Trial Sponsors for SYNTOCINON

Sponsor Name

Sponsor Name for SYNTOCINON
Sponsor	Trials
Cairo University	14
University of California, San Francisco	12
Massachusetts General Hospital	9

Sponsor Type

Sponsor Type for SYNTOCINON
Sponsor	Trials
Other	199
U.S. Fed	14
NIH	10